The new Cannabis Ventures offers readers this easy reading of BDSA’s Cannabis for 15 monthly data states.
The sale of Cannabis in August increased by 0.5%, which decreased for 2.7%. In this review, we share the results by the state, from Western markets, then concluding with the Eastern markets. In general, BDSA estimates that the sale in 15 markets in July amounted to $ 2.20 billion, which increased by 6.3% a year ago. Excluding the great interest in New York, which I explain below has increased by 1.6%.
Western markets
BDSA provides coverage for Arizona, California, Colorado, Nevada and Oregon. In August, the growth of year was negative in all 5 states, except for the one, for which the growth rate was 1.4% in California. Growth in all these countries has increased successively.
Eastern markets
BDSA provides coverage of Florida, Illinois, Maryland, Massachusetts, Michigan, Missouri, New Jersey, New York, Ohio and Pennsylvania. In August, the growth of year was ranging from Michigan to Up to + 989.6%, which was the sale of its adults, which included BDSA since January, but first of all included a few months ago. Ohio began the use of adults in August and was growing quite high in the previous months. It should be noted that in Florida and Pennsylvania are medical markets. Sequential growth was the negative five market and fell in these five markets based on the day. The annual growth remained except for three states. We warn about Florida, which can be slowed down, despite the strong growth of the dispensary and the scope, competitive pressure, and it was less than two years ago in the beginning of this year. The state has never seen a decline until March.
For readers who are interested in a deeper form Cannabis markets in these fifteen countries And moreover, including additional product categories, brand and product details, longer history and product features, learn how BDSA solutions can provide you with actions and analysis.
Based on the Houston, Alan cries out his experience as the founder of the online community 420 InvestorThe first and still the biggest decent diligent platform focused on the shares sold in the cannabis industry. Alan continues to find new ways to connect industry and facilitate its sustainable growth in the Canepuni community. Approximately New hemp enterprisesHe is responsible for content development and strategic alliances. Until the early 2013 focuses on the cannabis industry, Alan, who began his career in Wall Street, worked as more than two decades of research and portfolio. Article 650 of the Article 650 published in 2007 Looking for alphaWhere he has 70,000 followers, Alan is a frequent speaker for industry conferences and a Frequent source The media, including NY Times, Wall Street Journal, Fox Business and Bloomberg TV. Contact Alan. Ration | Facebook | Connection | Email
Vireo Growth Inc. Announces Fourth Quarter 2025 Results
Q4 GAAP revenue of $104.5 million was up 317.7% year-over-year, driven by recently closed M&A deals.
In Q4, same-store sales were up 22% year-over-year and wholesale revenue was up 55% year-over-year; Excluding Minnesota, same-store sales rose 11.3% year-over-year
Announced pending acquisitions of Eaze, Schwazze and PharmaCann retail assets in Colorado, as well as an MOU for the Hawthorne acquisition, all of which are expected to close in the first half of 2026.
The company closed the fourth quarter with $122.5 million in cash; expects to remain obtainable
MINNEAPOLIS, March 17, 2026 (GLOBE NEWSWIRE) — Vireo Growth Inc. (“Vireo” or the “Company”) (CSE: VREO; OTCQX: VREOF), today reported financial results for its fourth fiscal quarter ended December 31, 2025. Key financial results are presented below in summary form, with accompanying commentary and from management of certain key operating metrics that the Company uses to evaluate its performance. All currency figures shown here are in US dollars.
Management Commentary
Chief Executive Officer John Mazarakis commented: “Fourth quarter performance remained in line with our expectations and reflected same-store sales growth excluding Minnesota’s 11.3% increase and wholesale’s 55% increase in the year-ago quarter. As we begin the new year, we will continue to optimize all areas of our business while maintaining opportunities for further growth.
Recent developments
On December 16, 2025, the Company entered into an asset purchase agreement through a wholly-owned subsidiary to acquire certain assets and property used in a cannabis dispensary operating in the state of Colorado owned by PharmaCann Inc. (“PharmaCann”). Under the terms of the agreement, the Company expects to issue subordinated voting stock with an estimated value of $49,000,000 and assume certain liabilities in exchange for the assets acquired. Stock compensation is subject to certain adjustments.
On December 22, 2025, the Company entered into a merger agreement and plan to acquire Eaze Inc. (“Eaze”) in a business combination transaction. Pursuant to the agreement, following the closing of the transaction, the Company expects to issue subordinate voting shares as consideration for the issued and outstanding shares of Eaze. The estimated closing consideration is approximately $47,000,000, subject to customary post-closing adjustments. The merger agreement also provides for the payment of potential earnings payable in subordinated voting shares of the Company based on Eaze’s future financial performance, subject to contractual restrictions.
On January 15, 2026, the Company entered into a non-binding memorandum of understanding (“MOU”) with ScottsMiracle-Gro regarding the potential acquisition of The Hawthorne Gardening Company LLC (“Hawthorne”).
At the end of the fourth quarter, the Company completed the integration of its recent acquisitions from Deep Roots, Proper, and Wholesome, including streamlined accounting, finance, human resources, insurance and procurement operations, and the implementation of a new enterprise resource planning system across the organization. As a result, the Company has already implemented corporate synergies.
Balance sheet and liquidity
As of December 31, 2025, total current assets, excluding Medicine Man Technologies Inc. (dba Schwazze) (“Schwazze”) receivables, assets held for sale and income taxes receivable, were $204.1 million, including cash of $122.5 million. Total current liabilities, excluding uncertain tax liabilities, were $71.6 million. As of December 31, 2025, the Company had a total of 1,177,624,278 shares of subordinate voting stock outstanding on a treasury method basis at a par value of $0.60 per share.
Conference call and webcast information
Vireo’s management will hold a conference call with research analysts today, March 17, 2026 at 8:00 a.m. ET (7:00 a.m. CT) to discuss its financial results for the fourth quarter ended December 31, 2025. 1-646-307-1963 (Toll Free) (International) and the conference ID number is 9471311.
A live audio webcast of this event will also be available on the Events and Presentations section of the Company’s Investor Relations website and via the following link: https://events.q4inc.com/attendee/171708452.
About Vireo Growth Inc
Vireo was founded in 2014 as a leading medical cannabis company. Vireo is building a disciplined, strategically aligned and execution-focused platform in the industry. This strategy drives our intense local market focus while leveraging the strength of the national portfolio. We are committed to hiring industry leaders and deploying capital and talent where we believe it will deliver the most value. Vireo operates with a long-term mindset, an action bias, and an unwavering commitment to its customers, employees, shareholders, industry partners, and the communities it serves. For more information about Vireo, visit www.vireogrowth.com.
New Cannabis Ventures’ NCV Newswire aims to gather high-quality content and information about leading cannabis companies to help our readers filter through the noise and stay on top of the most important cannabis business news. The NCV Newswire is edited by an editor and is not, however, automated. Got a secret news tip? Get in touch.
Michigan hemp sales for february decreased compared to a year ago, as they increased sequentially by 3.4%. Sales of $234.6 million decreased by 3.0% compared to last year.
The Michigan Cannabis Regulatory Agency breaks down sales by medical and adult use, with medical sales down 38.6% year over year to $0.4 million, down 3.8% sequentially, and adult use sales down 3.0% year over year to $234.2 million, down 3.4% sequentially.
The state breaks down sales by category and provides pricing details by category for both medical and adult;
For Adults – Use
Medical
As supply continues to expand, prices for adult flowers have plummeted. The average price of $945 a pound in January was up 1.3 percent sequentially from a record low in December and down 8.2 percent from a year ago.
Michigan hemp sales are expected to grow 82.1% to $1.79 billion in 2021, 27.9% to $2.29 billion in 2022, and 33.3% to $3.06 billion in 2023. billion In 2026, Michigan cannabis sales decreased by 5.7%.
Based in Houston, Alan leverages his experience as an online community founder 420 Investorthe first and still the largest due diligence platform focused on publicly traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. time New Cannabis Ventureshe is responsible for content development and strategic alliances. Before turning his attention to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst with more than two decades of research and portfolio management experience. A prolific writer, with over 650 articles published since 2007 Looking for Alphawhere he has 70,000 followers, Alan is a frequent speaker at industry conferences and frequent source Media including the NY Times, Wall Street Journal, Fox Business and Bloomberg TV. Contact Alan. Twitter: |: Facebook |: LinkedIn: |: El
Verano Announces Fourth Quarter and Full Year 2025 Financial Results
The company delivered sequential revenue and margin improvement within guidance in the fourth quarter; closes 2025 with the top three market share positions1 in all competing categories
The newly announced $195 million credit facility demonstrates the Company’s ability to access lower cost capital and secure some of the industry’s most favorable terms, including maturity and prepayment flexibility and an initial interest rate of 9.5% per annum.
CHICAGO, March 12, 2026 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“Verano” or the “Company”), a leading multinational cannabis company, today announced its financial results for the fourth quarter and full year ended December 31, 2025, prepared in accordance with US Generally Accepted Accounting Principles (“US GAAP”).
Financial highlights for the fourth quarter and full year of 2025
New Cannabis Ventures’ NCV Newswire aims to gather high-quality content and information about leading cannabis companies to help our readers filter through the noise and stay on top of the most important cannabis business news. The NCV Newswire is edited by an editor and is not, however, automated. Got a secret news tip? Get in touch.
